Zydus Lifesciences has entered into an exclusive licensing agreement with Germany-based Formycon AG to commercialise FYB206, a biosimilar of the immunotherapy drug Keytruda (pembrolizumab), in the United States and Canada. Under this partnership, Formycon will oversee product development, regulatory submissions and manufacturing, while Zydus’ subsidiary, Zydus Lifesciences Global FZE, will handle marketing and distribution across the two key North American markets.

FYB206 is nearing completion of its clinical development, and Formycon plans to submit a Biologics Licence Application to the US Food and Drug Administration in the near future. Once approved, the biosimilar is expected to offer a more affordable alternative to one of the world’s most widely used immunotherapies for multiple cancer types.

Zydus Managing Director Dr. Sharvil P. Patel noted that the agreement marks the company’s entry into the North American biosimilar segment and signals the expansion of its immunotherapy portfolio overseas. He also highlighted that the move aligns with Zydus’ ongoing plans to acquire manufacturing facilities in California, which are expected to support future production and commercial activities.

Formycon’s leadership stated that the partnership combines its expertise in biosimilar development with Zydus’ strong commercial network, creating an opportunity to broaden access to an important oncology treatment. The companies emphasised that FYB206 carries strong commercial potential, given the significant global demand for pembrolizumab-based therapies.

With Keytruda generating close to USD 30 billion in annual global sales, the introduction of FYB206 could play a meaningful role in expanding patient access to immunotherapy while reducing healthcare costs. Both partners see this collaboration as a strategic step forward in shaping the biosimilar landscape in North America.